Evidence map›Paper›PMID 37745656›Full record

ArticleFrontiers in neurology2023

Oculomotor analysis to assess brain health: preliminary findings from a longitudinal study of multiple sclerosis using novel tablet-based eye-tracking software.

Étienne de Villers-Sidani, Patrice Voss, Natacha Bastien, J Miguel Cisneros-Franco, Shamiza Hussein, Nancy E Mayo, Nils A Koch, Alexandre Drouin-Picaro, François Blanchette, Daniel Guitton and 1 more

Abstract read
In one paragraph

Article in Frontiers in neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. From progression to progress: The future of multiple sclerosis.Journal of central nervous system disease · 2024
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Étienne de Villers-SidaniInnodem Neurosciences, Montreal, QC, Canada.
Patrice VossInnodem Neurosciences, Montreal, QC, Canada.
Natacha BastienNovartis Pharmaceuticals Canada Inc., Montreal, QC, Canada.
J Miguel Cisneros-FrancoInnodem Neurosciences, Montreal, QC, Canada.
Shamiza HusseinNovartis Pharmaceuticals Canada Inc., Montreal, QC, Canada.
Nancy E MayoFaculty of Medicine, School of Physical and Occupational Therapy, McGill University, Montreal, QC, Canada.
Nils A KochInnodem Neurosciences, Montreal, QC, Canada.
Alexandre Drouin-PicaroInnodem Neurosciences, Montreal, QC, Canada.
François BlanchetteNovartis Pharmaceuticals Canada Inc., Montreal, QC, Canada.
Daniel GuittonMontreal Neurological Institute, McGill University, Montreal, QC, Canada.
Paul S GiacominiInnodem Neurosciences, Montreal, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A growing body of evidence supports the link between eye movement anomalies and brain health. Indeed, the oculomotor system is composed of a diverse network of cortical and subcortical structures and circuits that are susceptible to a variety of degenerative processes. Here we show preliminary findings from the baseline measurements of an ongoing longitudinal cohort study in MS participants, designed to determine if disease and cognitive status can be estimated and tracked with high accuracy based on eye movement parameters alone. Using a novel gaze-tracking technology that can reliably and accurately track eye movements with good precision without the need for infrared cameras, using only an iPad Pro embedded camera, we show in this cross-sectional study that several eye movement parameters significantly correlated with clinical outcome measures of interest. Eye movement parameters were extracted from fixation, pro-saccade, anti-saccade, and smooth pursuit visual tasks, whereas the clinical outcome measures were the scores of several disease assessment tools and standard cognitive tests such as the Expanded Disability Status Scale (EDSS), Brief International Cognitive Assessment for MS (BICAMS), the Multiple Sclerosis Functional Composite (MSFC) and the Symbol Digit Modalities Test (SDMT). Furthermore, partial least squares regression analyses show that a small set of oculomotor parameters can explain up to 84% of the variance of the clinical outcome measures. Taken together, these findings not only replicate previously known associations between eye movement parameters and clinical scores, this time using a novel mobile-based technology, but also the notion that interrogating the oculomotor system with a novel eye-tracking technology can inform us of disease severity, as well as the cognitive status of MS participants.

Indexed as

BICAMSdigital biomarkerEDSSmachine learningmobile eye-trackerMSFCmultiple scleorsisSDMT

Identifiers

PMID37745656
PMCPMC10516298

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.